BRPI0813520A2 - Anticorpo monoclonal citotóxico anticâncer - Google Patents

Anticorpo monoclonal citotóxico anticâncer

Info

Publication number
BRPI0813520A2
BRPI0813520A2 BRPI0813520-7A2A BRPI0813520A BRPI0813520A2 BR PI0813520 A2 BRPI0813520 A2 BR PI0813520A2 BR PI0813520 A BRPI0813520 A BR PI0813520A BR PI0813520 A2 BRPI0813520 A2 BR PI0813520A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
cytotoxic monoclonal
cytotoxic
antibody
monoclonal
Prior art date
Application number
BRPI0813520-7A2A
Other languages
English (en)
Inventor
David S F Young
Helen P Findlay
Susan E Hahn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0813520A2 publication Critical patent/BRPI0813520A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023Lung
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1054Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0813520-7A2A 2007-07-16 2008-07-14 Anticorpo monoclonal citotóxico anticâncer BRPI0813520A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94993507P 2007-07-16 2007-07-16
PCT/CA2008/001290 WO2009009883A1 (en) 2007-07-16 2008-07-14 An anti-cancer cytotoxic monoclonal antibody

Publications (1)

Publication Number Publication Date
BRPI0813520A2 true BRPI0813520A2 (pt) 2014-12-23

Family

ID=40259251

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813520-7A2A BRPI0813520A2 (pt) 2007-07-16 2008-07-14 Anticorpo monoclonal citotóxico anticâncer

Country Status (9)

Country Link
US (1) US20090022660A1 (pt)
EP (1) EP2178920A1 (pt)
KR (1) KR20100021659A (pt)
CN (1) CN101743256A (pt)
AU (1) AU2008278229A1 (pt)
BR (1) BRPI0813520A2 (pt)
CA (1) CA2692826A1 (pt)
TW (1) TW200918559A (pt)
WO (1) WO2009009883A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191119A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191120A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518393A (ja) * 2001-12-21 2005-06-23 アリアス リサーチ、インコーポレイテッド 個別化抗癌抗体
US20080206133A1 (en) * 2007-01-23 2008-08-28 Young David S F Cancerous Disease Modifying Antibodies
US20080213170A1 (en) * 2007-01-23 2008-09-04 Young David S F Cancerous Disease Modifying Antibodies
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
US20090022660A1 (en) 2009-01-22
CA2692826A1 (en) 2009-01-22
WO2009009883A1 (en) 2009-01-22
AU2008278229A1 (en) 2009-01-22
TW200918559A (en) 2009-05-01
KR20100021659A (ko) 2010-02-25
CN101743256A (zh) 2010-06-16
EP2178920A1 (en) 2010-04-28

Similar Documents

Publication Publication Date Title
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
NO344963B1 (no) Humanisert antistoff
SMT201700083B (it) Anticorpi monoclonali
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2274012T3 (da) Cytotoksisk immunoglobulin
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0819165A2 (pt) Anticorpos anti-vegf
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
DK2131860T3 (da) Anti-sclerostin-antistoffer
ZA201000049B (en) Monoclonal antibeta amyloid antibody
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BRPI0809677A2 (pt) Anticorpos anti-ige
BRPI0820819A2 (pt) Formulação de anticorpos
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
SG10201601279SA (en) Monoclonal Antibody STRO-4
DK2059533T3 (da) Multispecifikke antistoffer
BRPI0720218A2 (pt) Anticorpos monoclonais contra angptl3
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
EP2331579A4 (en) MONOCLONAL ANTIBODIES
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0815567A2 (pt) Anticorpos híbridos antialfa v-integrina projetados

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C07K 16/30; A61K 39/395; A61K 47/48; A61K 51/10; A61P 35/00; A61P 37/04; C07K 16/46; C12N 5/16; C12P 21/08; G01N 33/574; G01N 33/577; C07K 14/705; C07K 19/00.

Ipc: C07K 16/30 (2006.01), A61K 47/68 (2017.01), A61K 5

Ipc: C07K 16/30 (2006.01), A61K 47/68 (2017.01), A61K 5

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/30 (2006.01), A61K 47/68 (2017.01), A61K 5